Merck, GSK, J&J Broaden Strategic LP Relationships, External Discovery Initiatives
In the latest examples of biotech VCs and Big Pharma joining forces to prospect for products, Index Ventures announced in March that it had raised a new €150 million life sciences venture fund, Index Life VI, and said that GSK and J&J had committed a combined 50% of the fund’s total capital. Three weeks later Merck said it added early-stage life science venture firm Flagship Ventures to the roster of venture funds it has joined as a limited partner. The investments signal continued interest in externalizing discovery and early-stage development by industry and feature new steps in an ongoing dance between industry’s largest players and the venture investors at the forefront of building biotechs and identifying promising assets.
More from Business Strategy
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
More from In Vivo
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.




